VAV1 gene mutations trigger T-cell tumours in mice

13 Oct 2020
VAV1 gene mutations trigger T-cell tumours in mice

Life is an exquisite orchestration of growth and change, with checks and balances that fine-tune complex entwined interactions, both intrinsic and external.

White blood cells (WBC) are integral to an organism's immune defenses against disease and invasion; unfortunately, these mechanisms may go awry causing uncontrolled increases in dysfunctional cell numbers, resulting in tumour formation.

Now, researchers at the University of Tsukuba have illustrated how mutations in a specific gene called VAV1 may promote tumours involving a type of white blood cell, the T-cell, in experimental mice.

Leukocytes, or WBC, are fundamental to the body's immune function.

They include B-lymphocytes that generate antibodies, as well as thymic-lymphocytes or T-cells with diverse immune-related functions, so called because they develop in the thymus gland.

T-cell neoplasms include a mature subtype called peripheral T-cell lymphoma.

Studies have shown that VAV1, a gene that participates in T-cell receptor signaling, is altered in several peripheral T-cell lymphoma variants; therefore, the research team sought to elucidate the role of VAV1 mutants in the malignant transformation of T-cells in vivo.

The tumour suppressor gene p53 is called 'guardian of the genome' because it prevents genome mutation.

The researchers replicated VAV1 mutations found in human T-cell tumours in both normal ("wild-type") mice and mice lacking p53.

Lead author Kota Fukumoto describes their findings: "No tumours developed in the wild-type mice with VAV1 mutations over a year of observation; whereas immature tumours developed in mice that lacked p53.

Remarkably, mice that both lacked p53 and had mutations in VAV1 developed mature tumours resembling human peripheral T-cell lymphoma, and had poorer prognosis than the mice lacking p53 only."

The team also transplanted tumour cells into mice that lacked a functional thymus.

The results suggested that tumour initiation was likely due to mechanisms within the cell itself.

"We noted that T-cell tumours with VAV1 mutation showed Myc pathway enrichment, as well as somatic copy number alterations (SCNAs), including at the Myc locus," explains Professor Shigeru Chiba, senior author.

Significantly, Myc, a family of regulator genes and proto-oncogenes, and SCNAs, which cause discrepancies in DNA copies, are both distinct hallmarks of tumour formation.

"Interestingly, pharmaceutical inhibition of the Myc pathway increased overall survival of mice harboring VAV1-mutant tumours," Professor Chiba adds.

"Therefore, our methodology and results suggest that the VAV1-mutant expressing mice developed in this study could be a research tool for evaluating therapeutic agents directed against specific T-cell neoplasms."